Hosted on MSN

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, ...
Benzinga.com

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms ...
Rutland Herald

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

KELOWNA, BC / / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a ...
Nasdaq

Lexaria Meets Primary Endpoint In Phase 1b GLP-1-H24-4 Study; Updates On Secondary Endpoint Majors

(RTTNews) - Lexaria Bioscience Corp. (LEXX, LEXXW) announced that it has achieved the safety and tolerability-based final primary endpoint on Phase 1b,12-week chronic study GLP-1-H24-4 on 4 ...

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Assessments of the magnitude of decreases in glycated haemoglobin (" HbA1c "), as a primary blood test for blood sugar levels, and body weight were the major secondary efficacy endpoints of the Study.